Rohto Pharmaceutical Co.,Ltd.
Notice Regarding Share Buyback (Acquisition of Treasury Stock Based on the Provisions of Article 459, Paragraph 1 of the Companies Act)
Rohto Pharmaceutical Co., Ltd. will acquire up to 1,500,000 shares of treasury stock through market purchases from March 27, 2026 to December 31, 2026, with a total purchase price of up to 3 billion yen to improve capital efficiency.
Key Figures
- Maximum number of shares to be acquired: 1,500,000 shares (0.66% of total issued common shares)
- Maximum acquisition price: 3 billion yen
- Acquisition period: From March 27, 2026 to December 31, 2026
AI要約
Overview of Capital Policy
Rohto Pharmaceutical Co., Ltd. has resolved to acquire treasury stock aiming to improve capital efficiency and implement agile capital policies. The target shares are the company's common stock, with an upper limit of 1,500,000 shares (0.66% of total issued common shares), and a total acquisition price of up to 3 billion yen. The acquisition period is from March 27, 2026 to December 31, 2026, and the acquisition method is market purchase on the Tokyo Stock Exchange.
Impact on Shareholders and Current Status
As of March 26, 2026, the total number of issued shares is 236,178,310 shares (including treasury stock), the number of treasury shares is 10,213,970 shares, and the total issued shares excluding treasury stock is 225,964,340 shares. This share buyback plans to acquire approximately 0.66% of the total issued shares and is expected to contribute to improving capital efficiency. Although specific fund usage is not stated, the objective is to implement agile capital policies.
